Keep pulling the thread on Laura Deming and Jacob Kimmel.
A 2023 study by the Bischoff Group demonstrated the successful reversible cryopreservation of a rat kidney, which was then transplanted into a rat that subsequently returned to normal function.
New Limit identified its first preclinical candidate molecule in late 2023 and is now scaling up manufacturing for trials in monkeys.
New Limit's AI models can explain approximately 50% of the experimental variation in transcription factor effects in silico, significantly improving prediction accuracy.
Using AI models in an active learning loop has made New Limit's discovery process for effective transcription factor sets approximately twice as fast compared to human-led prioritization.
Jacob Kimmel predicts that the trend of Eroom's Law, the rising cost of drug development, will begin to reverse due to efficiencies from AI.
Current AI models for antibody design can generate sequences where approximately one in five are viable as development candidates for human trials.
Jacob Kimmel believes AI represents the second major revolution in therapeutic development, following the recombinant DNA revolution of the 1970s-80s that led to companies like Genentech, Amgen, and Vertex.
New Limit expects to have sufficient data by the end of the current year to decide whether to advance its first therapeutic candidate into human clinical trials.
The long-term vision for the company Until is to create hibernation pods for whole organisms.
New Limit allocates its R&D budget with a roughly 70/30 split between near-term, lower-risk projects and longer-term, higher-risk investments.
By adopting a pooled, multiplexed approach for molecular construction, New Limit can test approximately five times as many transcription factor combinations per dollar invested.
The use of AI models at Until has resulted in at least a 2x speed improvement in research and development iteration cycles.